尼妥珠单抗联合IMRT治疗根治性放化疗后局部复发食管癌的临床研究

Clinical Study of Nimotuzumab Combined with IMRT in the Treatment of Local-recurrence Esophageal Carcinoma after Radical Chemoradiotherapy

目的:探讨尼妥珠单抗联合调强放疗(IMRT)治疗根治性放化疗后局部复发食管癌患者的有效性和安全性。方法:37例食管癌患者随机分为2组,观察组19例,予尼妥珠单抗联合IMRT治疗;对照组18例行IMRT治疗,比较2组患者近期疗效,并对患者进行随访,比较2组患者生存率和不良反应率。结果:观察组近期有效率(84.21%)高于对照组(50.00%)(P<0.05);观察组与对照组1、2、3年生存率分别为63.16%、42.11%、15.79%和44.44%、27.78%、5.56%;差异无统计学意义(P>0.05);2组不良反应比较差异无统计学意义(P>0.05)。结论:尼妥珠单抗联合IMRT治疗根治性放化疗后局部复发食管癌患者可提高近期有效率。

Objective:To investigate the efficacy and safety of nimotuzumab concurrent with intensity-modulated radiotherapy (IMRT) for patients with local-recurrence esophageal carcinoma after definitive chemoradiotherapy. Methods: Thirty-seven patients were randomly divided into the trial group (19 patients) and the control group (18 patients). Nineteen patients of the trial group received nimotuzumab concurrent IMRT;eighteen patients of the control group received IMRT only. Results: The resent response rate (RR) of the trial group and control group were 84.21% and 50.00%(P<0.05);The 1-, 2-, 3-survival rates of the trial group and control group were 63.16%、42.11%、15.79% and 44.44%、27.78%、5.56% respectively, but the difference was not statistically significant (P>0.05);The adverse effects of the two groups were similar and the difference was not statistically significant (P>0.05). Conclusion: Nimotuzumab concurrent with IMRT could significantly increase RR in the patients with local-recurrence esophageal carcinoma after definitive chemoradiotherapy, and improve the 1-, 2-, and 3-yearsurvival rate of patients to some degree.